# FDA 483 - Richard D. Guyer, MD - February 10, 2020

Source: https://www.globalkeysolutions.net/records/483/richard-d-guyer-md/dbe47349-04c9-49b1-9232-d04967bfbabd

> FDA 483 for Richard D. Guyer, MD on February 10, 2020. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Richard D. Guyer, MD
- Inspection Date: 2020-02-10
- Product Type: other
- Office Name: Dallas District Office
- Summary: An FDA inspection of Richard D. Guyer, MD, a clinical investigator in Plano, TX, revealed significant deficiencies in conducting a clinical investigation. The firm failed to adhere to the signed investigator's agreement and study protocol, leading to issues with subject eligibility and the proper reporting of adverse events. These findings indicate a lack of control over critical aspects of clinical trial conduct.

## Related Officers

- [issuing_officer](https://www.globalkeysolutions.net/people/camille-d-brown/419869d2-1810-40ea-8e8a-687de7013f6a)
- [investigator](https://www.globalkeysolutions.net/people/marilyn-s-babu/681b6d89-afae-4a11-bed1-858792b172a6)

Company: https://www.globalkeysolutions.net/companies/richard-d-guyer-md/0b1e8b77-c09a-4144-8147-39ed4c0bc711

Office: https://www.globalkeysolutions.net/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9